Online inquiry

IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ2402MR)

This product GTTS-WQ2402MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets CD3E&EPCAM gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Mus musculus
RefSeq NM_000733.4; NM_002354.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 4072
UniProt ID P07766; P16422
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&EPCAM, AMG 110(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ2402MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ382MR IVTScrip™ mRNA-Anti-TYRP1, 20D7S(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 20D7S
GTTS-WQ8444MR IVTScrip™ mRNA-Anti-TLR3 Agonist, HspE7(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA HspE7
GTTS-WQ11166MR IVTScrip™ mRNA-Anti-IFNAR1, MDX-1333(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA MDX-1333
GTTS-WQ13571MR IVTScrip™ mRNA-Anti-IL13, QAX-576(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA QAX-576
GTTS-WQ13494MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA PRTX-100
GTTS-WQ10444MR IVTScrip™ mRNA-Anti-MSTN, LY-2495655(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA LY-2495655
GTTS-WQ1365MR IVTScrip™ mRNA-Anti-IL12B, ABT-874(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ABT-874
GTTS-WQ11741MR IVTScrip™ mRNA-Anti-IGF1R, MK-0646(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MK-0646
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW